Trial Profile
Open-label trial of Glivec (imatinib mesylate) in patients with primary or recurrent dermatofibrosarcoma protuberans.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 15 Oct 2015
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Dermatofibrosarcoma
- Focus Therapeutic Use
- 28 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Oct 2006 Status change
- 02 Oct 2006 The expected completion date for this trial is now 1 Jan 2007.